Systemic pharmacological treatment of digital ulcers in systemic sclerosis: a systematic literature review.

"a patient intervention comparison outcome (pico) model was applied to the research questions and search strategy which are detailed in supplementary data s1 and s2 available at rheumatology online.; the full text of all eligible citations was then independently assessed by the same reviewers (see supplementary data s3 for all full text articles excluded) and relevant study data extracted according to a prespecified template ( supplementary data s4 both available at rheumatology online)."

"Disclosure statement: M.H. has received speaking fees from Actelion Pharmaceuticals, Eli Lilly and Pfizer, outside of the submitted work, and is a member of a Data and Safety Monitoring Board for Certa Therapeutics. L.C. has served as an advisor and steering committee member for Eicos Sciences and has received consulting fees from Mitsubishi Tanabe, Genentech, Kyverna and Jasper. P.M. has received speaking fees from Actelion Pharmaceuticals and Boehringer Ingelheim. Y.A. has received consulting fees from Boehringer Ingelheim and Sanofi, payment or honoraria from Boehringer Ingelheim and participated in data safety or advisory boards for Boehringer Ingelheim, Menarini, Chemomab, Curzion, Medseni and Sanofi. C.P.D. has received grants from GlaxoSmithKline, Inventiva, CSL Behring, Servier and Arxx Therapeutics and consulting fees from GlaxoSmithKline, Janssen, Bayer, Sanofi, Inventiva, Boehringer Ingelheim, Roche, CSL Behring, Corbus and Acceleron. O.D. has a consultancy relationship with and/or has received research funding from and/or has served as a speaker for the following companies in the area of potential treatments for SSc and its complications in the last 3 calendar years: AbbVie, Acceleron, Alcimed, Amgen, AnaMar, Arxx, AstraZeneca, Baecon, Blade, Bayer, Boehringer Ingelheim, Corbus, CSL Behring, Galapagos, Glenmark, Horizon, Inventiva, Kymera, Lupin, Medscape, Miltenyi Biotec, Mitsubishi Tanabe, MSD, Novartis, Prometheus, Roivant, Sanofi and Topadur and holds a patent: ‘mir-29 for the treatment of systemic sclerosis’ (US8247389, EP2331143). T.F. has held a paid leadership role with the Scleroderma Clinical Trials Consortium. D.E.F. has received grants or contracts from Amgen, Corbus, CSL Behring, Galapagos, Gilead, GlaxoSmithKline, Horizon, Kadmon, Novartis, Pfizer, Roche/Genentech and Talaris; consulting fees from Amgen, Corbus, Galapagos, Horizon, Kadmon, Pfizer and Talaris and payment or honoraria from CME. D.K. has received consulting fees from Actelion Pharmaceuticals, Acceleron, Amgen, Bayer, Boehringer Ingelheim, Chemomab, CSL Behring, Genentech/Roche, Horizon, Paracrine Cell Therapy, Mitsubishi Tanabe and Prometheus and holds stock or stock options in Eicos Sciences. T.K. is a World Scleroderma Foundation board member, Edith Busch Foundation advisory board member and German Scleroderma Foundation board member. M.K. has received speaker fees from AbbVie, Asahi-Kasei, Astellas, Boehringer Ingelheim, Chugai, Eisai, Nippon Shinyaku, Ono Pharmaceuticals and Tanabe-Mitsubishi; consultant fees from AstraZeneca, Boehringer Ingelheim, Chugai, Corbus, GlaxoSmithKline, Horizon, Mochida, Kissei and grant/research support from Boehringer Ingelheim, MBL and Ono Pharmaceuticals. M.M.C. has received grants from Actelion Pharmaceuticals and consulting fees from Actelion Pharmaceuticals, Biogen, Bayer, Boehringer Ingelheim, CSL Behring and Eli Lilly. The remaining authors have declared no conflicts of interest."

"Funding This work was supported by the World Scleroderma Foundation Digital Ulcer Working Group. Disclosure statement: M.H. has received speaking fees from Actelion Pharmaceuticals, Eli Lilly and Pfizer, outside of the submitted work, and is a member of a Data and Safety Monitoring Board for Certa Therapeutics. L.C. has served as an advisor and steering committee member for Eicos Sciences and has received consulting fees from Mitsubishi Tanabe, Genentech, Kyverna and Jasper. P.M. has received speaking fees from Actelion Pharmaceuticals and Boehringer Ingelheim. Y.A. has received consulting fees from Boehringer Ingelheim and Sanofi, payment or honoraria from Boehringer Ingelheim and participated in data safety or advisory boards for Boehringer Ingelheim, Menarini, Chemomab, Curzion, Medseni and Sanofi. C.P.D. has received grants from GlaxoSmithKline, Inventiva, CSL Behring, Servier and Arxx Therapeutics and consulting fees from GlaxoSmithKline, Janssen, Bayer, Sanofi, Inventiva, Boehringer Ingelheim, Roche, CSL Behring, Corbus and Acceleron. O.D. has a consultancy relationship with and/or has received research funding from and/or has served as a speaker for the following companies in the area of potential treatments for SSc and its complications in the last 3 calendar years: AbbVie, Acceleron, Alcimed, Amgen, AnaMar, Arxx, AstraZeneca, Baecon, Blade, Bayer, Boehringer Ingelheim, Corbus, CSL Behring, Galapagos, Glenmark, Horizon, Inventiva, Kymera, Lupin, Medscape, Miltenyi Biotec, Mitsubishi Tanabe, MSD, Novartis, Prometheus, Roivant, Sanofi and Topadur and holds a patent: ‘mir-29 for the treatment of systemic sclerosis’ (US8247389, EP2331143). T.F. has held a paid leadership role with the Scleroderma Clinical Trials Consortium. D.E.F. has received grants or contracts from Amgen, Corbus, CSL Behring, Galapagos, Gilead, GlaxoSmithKline, Horizon, Kadmon, Novartis, Pfizer, Roche/Genentech and Talaris; consulting fees from Amgen, Corbus, Galapagos, Horizon, Kadmon, Pfizer and Talaris and payment or honoraria from CME. D.K. has received consulting fees from Actelion Pharmaceuticals, Acceleron, Amgen, Bayer, Boehringer Ingelheim, Chemomab, CSL Behring, Genentech/Roche, Horizon, Paracrine Cell Therapy, Mitsubishi Tanabe and Prometheus and holds stock or stock options in Eicos Sciences. T.K. is a World Scleroderma Foundation board member, Edith Busch Foundation advisory board member and German Scleroderma Foundation board member. M.K. has received speaker fees from AbbVie, Asahi-Kasei, Astellas, Boehringer Ingelheim, Chugai, Eisai, Nippon Shinyaku, Ono Pharmaceuticals and Tanabe-Mitsubishi; consultant fees from AstraZeneca, Boehringer Ingelheim, Chugai, Corbus, GlaxoSmithKline, Horizon, Mochida, Kissei and grant/research support from Boehringer Ingelheim, MBL and Ono Pharmaceuticals. M.M.C. has received grants from Actelion Pharmaceuticals and consulting fees from Actelion Pharmaceuticals, Biogen, Bayer, Boehringer Ingelheim, CSL Behring and Eli Lilly. The remaining authors have declared no conflicts of interest."